

**Client:** Justin Tanger (NHNootropics)  
**Sample:** Emoxypine Succinate **Lot:** ES4  
**Report Date:** 3/5/2025  
**Test:** Purity


**Receipt Date:** 3/3/2025  
**Analysis Date:** 3/4/2025  
**Matrix:** Powder  
**Number of samples:** 1

## Certificate of Analysis

**Purity: 99%**

<b>Data File</b>	20250304_MS2_posneg_Emoxipine succinate_LotES4_purity.d	<b>Sample Name</b>	Emoxipine succinate_LotES4_purity
<b>Sample Type</b>	Sample	<b>Position</b>	P2-D6
<b>Instrument Name</b>	Instrument 1	<b>User Name</b>	
<b>Acq Method</b>	PuritydefaultMS2.m	<b>Acquired Time</b>	3/4/2025 5:22:35 PM (UTC-08:00)
<b>IRM Calibration Status</b>	Not Applicable	<b>DA Method</b>	20211216_PIS7_165and211_quad_SCAN_POS_Nowar taDSDPRWV_neat.m
<b>Comment</b>		<b>Info.</b>	
<b>Sample Group</b>		<b>Acquisition Time (Local)</b>	3/4/2025 5:22:35 PM (UTC-08:00)
<b>Stream Name</b>	LC 1		
<b>Acquisition SW Version</b>	6400 Series Triple Quadrupole B.09.00 (B9037.0)		

### Chromatograms



### Peak List

Time	Area	%Area
2.427 min.	77.9	1.01%
2.961 min.	7650.87	98.99%

Reviewed and Approved By:

*Herman Lelie*

Herman Lelie Ph.D Director of R&D